ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

JANX Janux Therapeutics Inc

47,39
0,29 (0,62%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Janux Therapeutics Inc JANX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,29 0,62% 47,39 06:00:13
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
47,08 46,51 48,23 47,39 47,10
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
08.3.202422:47EDGAR2Form S-8 - Securities to be offered to employees in employee..
08.3.202422:23EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08.3.202422:11EDGAR2Form 8-K - Current report
08.3.202422:01BWJanux Therapeutics Reports Fourth Quarter and Full Year 2023..
29.2.202423:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29.2.202423:11EDGAR2Form 8-K - Current report
29.2.202407:22BWJanux Therapeutics Announces Pricing of $296.5 Million..
29.2.202403:55EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
28.2.202423:15EDGAR2Form 8-K - Current report
28.2.202403:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27.2.202423:23EDGAR2Form 8-K - Current report
27.2.202423:00BWJanux Therapeutics Announces Proposed Public Offering of..
26.2.202422:05BWJanux Announces Encouraging Safety and Efficacy Data in..
20.2.202414:00BWJanux Therapeutics to Host Virtual Event Discussing Updated..
09.2.202422:31EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01.2.202422:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.1.202415:00BWJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo,..
03.1.202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:45EDGAR2Form 3 - Initial statement of beneficial ownership of..
07.11.202322:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202322:07EDGAR2Form 8-K - Current report
07.11.202322:01BWJanux Therapeutics Reports Third Quarter 2023 Financial..
08.9.202300:14EDGAR2Form 144 - Report of proposed sale of securities
14.8.202322:33EDGAR2Form 144 - Report of proposed sale of securities
08.8.202322:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202322:17EDGAR2Form 8-K - Current report
08.8.202322:01BWJanux Therapeutics Reports Second Quarter 2023 Financial..
18.7.202323:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18.7.202322:16EDGAR2Form 8-K - Current report
17.7.202314:45BWJanux Therapeutics Announces Pricing of $60 Million..
17.7.202314:16EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
17.7.202314:06EDGAR2Form 8-K - Current report
17.7.202314:00BWJanux Therapeutics Announces Positive Interim Clinical Data..
05.6.202322:35BWJanux Therapeutics Appoints Zachariah McIver, D.O., Ph.D.,..
09.5.202322:01BWJanux Therapeutics Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock